Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–877 of 877 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Endocrine Clear all
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340
View directory record Official record
Conditions
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
55
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 8, 2026, 1:30 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption

NCT02520258
View directory record Official record
Conditions
Glucose Metabolism Disorder
Interventions
Oral glucose tolerance test (OGTT), Diet soda containing aspartame only
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Nov 8, 2026, 1:30 PM EST
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Nov 8, 2026, 1:30 PM EST
Recruiting Phase 3 Interventional

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1240
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 813 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 8, 2026, 1:30 PM EST
Terminated Not applicable Interventional

SMART-ER: Symptom Monitoring With Patient-reported Outcomes

NCT05560685
View directory record Official record
Conditions
Breast Cancer
Interventions
Outcomes4Me, Semi-structured interview
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 8, 2026, 1:30 PM EST
Terminated No phase listed Observational

Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer

NCT02139774
View directory record Official record
Conditions
Prostate Cancer
Interventions
Walk with Ease
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Nov 8, 2026, 1:30 PM EST
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

NCT02422615
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Ribociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
26
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Nov 8, 2026, 1:30 PM EST
Active, not recruiting Phase 3 Interventional Results available

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 105 Years
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 8, 2026, 1:30 PM EST
Terminated Not applicable Interventional

Continuous Glucose Monitoring and Diabetes

NCT05840250
View directory record Official record
Conditions
Diabetes
Interventions
Continuous Glucose Monitoring and Education Support
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Nov 8, 2026, 1:30 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Adolescents

NCT04089332
View directory record Official record
Conditions
Insulin Resistance
Interventions
Oral Glucose Tolerance Test (OGTT), 3 Tesla MRI, Intravenous Catheter, Cognitive Tests
Other · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Nov 8, 2026, 1:30 PM EST
Active, not recruiting Phase 2 Interventional

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

NCT05090358
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
Interventions
Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin
Dietary Supplement · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 8, 2026, 1:30 PM EST
Terminated Not applicable Interventional Results available

Efficacy of Continuous Glucose Monitoring in Neonates With Hypoglycemia

NCT02300285
View directory record Official record
Conditions
Hypoglycemia, Newborn Morbidity
Interventions
Continuous Glucose Monitoring
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 60 Days
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 8, 2026, 1:30 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Benzoates - an Obesogenic Endocrine Disrupting Chemical

NCT03190785
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Benzoic acid washout and exposure
Other
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Nov 8, 2026, 1:30 PM EST